The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype

被引:78
作者
Nguyen, M
Lee, MC
Wang, JL
Tomlinson, JS
Shao, ZM
Alpaugh, ML
Barsky, SH [1 ]
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Med, Div Surg Oncol, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, Sch Med, Revlon UCLA Breast Ctr, Los Angeles, CA 90024 USA
关键词
thrombospondin-l; hypoxia inducible factor-1; angiogenic inhibitors; angiogenic factors;
D O I
10.1038/sj.onc.1203677
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human myoepithelial cells which surround ducts and acini of certain organs such as the breast form a natural border separating epithelial cells from stromal angiogenesis. Myoepithelial cell lines (HMS-1-6), derived from diverse benign myoepithelial tumors, all constitutively express high levels of active angiogenic inhibitors which include TIMP-1, thrombospondin-1 and soluble bFGF receptors but very low levels of angiogenic factors. These myoepithelial cell lines inhibit endothelial cell chemotaxis and proliferation. These myoepithelial cell lines sense hypoxia, respond to low O-2 tension by increased HIF-1 alpha but with only a minimal increase in VEGF and iNOS steady state mRNA levels. Their corresponding xenografts (HMS-X-6X) grow very slowly compared to their non-myoepithelial carcinomatous counterparts and accumulate an abundant extracellular matrix devoid of angiogenesis but containing bound angiogenic inhibitors. These myoepithelial xenografts exhibit only minimal hypoxia but extensive necrosis in comparison to their non-myoepithelial xenograft counterparts. These former xenografts inhibit local and systemic tumor-induced angiogenesis and metastasis presumably from their matrix-bound and released circulating angiogenic inhibitors. These observations collectively support the hypothesis that the human myoepithelial cell (even when transformed) is a natural suppressor of angiogenesis.
引用
收藏
页码:3449 / 3459
页数:11
相关论文
共 32 条
[1]  
Alpaugh ML, 1999, CANCER RES, V59, P5079
[2]  
[Anonymous], 1995, The molecular basis of cancer
[3]   SPECIFIC-INHIBITION OF ENDOTHELIAL-CELL PROLIFERATION BY THROMBOSPONDIN [J].
BAGAVANDOSS, P ;
WILKS, JW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 170 (02) :867-872
[4]   A SIREN SONG FROM TUMOR-CELLS [J].
CAVENEE, WK .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :3-3
[5]   THE 16-KILODALTON N-TERMINAL FRAGMENT OF HUMAN PROLACTIN IS A POTENT INHIBITOR OF ANGIOGENESIS [J].
CLAPP, C ;
MARTIAL, JA ;
GUZMAN, RC ;
RENTIERDELRUE, F ;
WEINER, RI .
ENDOCRINOLOGY, 1993, 133 (03) :1292-1299
[6]   FIBROBLAST CELL-INTERACTIONS WITH HUMAN-MELANOMA CELLS AFFECT TUMOR-CELL GROWTH AS A FUNCTION OF TUMOR PROGRESSION [J].
CORNIL, I ;
THEODORESCU, D ;
MAN, S ;
HERLYN, M ;
JAMBROSIC, J ;
KERBEL, RS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (14) :6028-6032
[7]   CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells [J].
Dawson, DW ;
Pearce, SFA ;
Zhong, RQ ;
Silverstein, RL ;
Frazier, WA ;
Bouck, NP .
JOURNAL OF CELL BIOLOGY, 1997, 138 (03) :707-717
[8]   ANGIOGENIC FACTORS [J].
FOLKMAN, J ;
KLAGSBRUN, M .
SCIENCE, 1987, 235 (4787) :442-447
[9]   Seminars in medicine of the Beth Israel Hospital, Boston - Clinical applications of research on angiogenesis [J].
Folkman, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (26) :1757-1763
[10]  
FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P1